Tag: Ultra-rapid CAR-T manufacturing

Home / Ultra-rapid CAR-T manufacturing

Categories

FasTCAR-T GC012F demonstrated overall 100% response rate in newly diagnosed multiple myeloma

Introduction Even in transplant-eligible (TE) patients, typical first-line treatments for high-risk (HR) newly-diagnosed multiple myeloma (NDMM) have dismal outcomes. A high-efficacy, safe CAR-T trea...
ultra-rapid-car-t-manufacturing

Scan the code